top of page
The Professional Network for Healthcare Experts
Medicus Pharma licenses Pfizer CD228V antibody-drug conjugate in deal worth more than $1bn
Medicus Pharma has secured exclusive worldwide rights to Pfizer's CD228-targeted antibody-drug conjugate PF-08046031 in an oncology licensing agreement potentially worth more than $1 billion.
nuaxia
Sep 142 min read
FDA approves Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for 2026–2027 season
The updated Comirnaty formulation targets the XFG variant and will begin shipping immediately for eligible older adults and people aged five to 64 at increased risk of severe COVID-19.
nuaxia
Aug 282 min read
European Commission authorises Pfizer-BioNTech XFG-adapted COVID-19 vaccine for the 2026–2027 vaccination season
The updated vaccine is authorised for individuals aged six months and older and aligns the EU COVID-19 vaccination programme with the currently circulating XFG variant.
nuaxia
Jul 312 min read
Innovent Biologics and Pfizer Form $10bn+ Oncology Alliance Across 12 Cancer Programs
The partnership expands a global co-development model spanning ADCs, multispecific antibodies, and early-stage oncology assets across US and China markets.
nuaxia
May 302 min read
bottom of page